0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
   Cambridge, UK and Indianapolis, US -- 13 January 2020: Acacia Pharma 
Group plc (the "Company") (EURONEXT: ACPH), a hospital pharmaceutical 
company focused on the development and commercialisation of new nausea 
and vomiting treatments for surgical and cancer patients, announces that 
application has been made to Euronext Brussels for the admission of the 
8,994,667 Ordinary Shares of GBP0.02 each (the "New Ordinary Shares") to 
trading on Euronext Brussels ("Admission") to satisfy the terms of the 
EUR10 million equity subscription made by Cosmo Pharmaceuticals and the 
EUR10 million upfront licensing payment for the US rights to the product 
ByFavo.  The New Ordinary Shares will rank pari passu in all respects 
with the Company's existing Ordinary Shares in issue. Admission to 
listing is expected on 14 January 2020. 
 
   Following issue of the New Ordinary Shares, the Company's total issued 
share capital will consist of 63,882,865 Ordinary Shares with one voting 
right per share. The Company does not hold any Ordinary Shares in 
Treasury. Therefore, following the issue of the New Ordinary Shares, the 
total number of voting rights in the Company is 63,882,865. 
 
   Contacts 
 
   Acacia Pharma Group plc 
 
   Mile Bolinder, CEO 
 
   Christine Soden, CFO 
 
   +44 1223 919760 
 
   https://www.globenewswire.com/Tracker?data=PzEmt7HSNgCzEfGJfWR0_Yt2h6ie8UUWRdYEqFiGxBwzRWIfen4flDruA-fslndntQcHMV3ue4A6LePgH2CR3QLGk1qZEbF2jsqNk5vghnD_eGAh03oRXgoqIbyeOXHCEJwfPlHzWmhKxgPC0Zc6oAZphhgug8oDFF5wbryUg4JKunDmdVOSHRNyxV2RCxyhDUNBqyhudk29PIQ9_EiAd4LGosviamEHeZeSc26gvXTnBG3oL1fI1sq9i-Xoc80OogOOXGZNWAMJuXRGD4T-Qg== 
IR@acaciapharma.com 
 
   Citigate Dewe Rogerson (Financial PR) 
 
   Mark Swallow, Frazer Hall, David Dible 
 
   +44 20 7638 9571 
 
   https://www.globenewswire.com/Tracker?data=MBW9s0DeLKjqPRTwqo4N-Ix1JuGznbQHM5yuAlQuI371LmnJeEJfaQyfnLcs9rPFWqhPA93E9CPA4EXMhSYsYYXYPxqmuKkblKnE3PLyNbVkhC6l2TVMevGi7ISNTeTY0mfpJPIDYUfmUYSX1LFfSabSERAML3LID927pE3umQIOa3RvuwT74kgThub6O8sZuZlJIA4yWBEq4FyIL7ahcywyJXUE69cEmWjdetyH3A4Ka2PMoGVjqGvNxsb-bsxknEedYhqOqcXvXx6akObFXFfP93FCP-G8L8PS_ULe_HsyPtCTBJHQaRy8J7BIWcoOOsOQeiaeW5rtB3EzklEhGw== 
acaciapharma@citigatedewerogerson.com 
 
 
 
 

(END) Dow Jones Newswires

January 13, 2020 11:59 ET (16:59 GMT)

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Apr 2023 a Apr 2024